Welcome to our dedicated page for Inspira Technologies Oxy Bhn news (Ticker: IINN), a resource for investors and traders seeking the latest updates and insights on Inspira Technologies Oxy Bhn stock.
Inspira Technologies Oxy BHN Ltd (IINN) delivers innovative respiratory care solutions through its non-invasive INSPIRA ART system and HYLA blood monitoring technology. This page provides investors and healthcare professionals with essential updates on regulatory milestones, product developments, and clinical partnerships shaping the future of critical care.
Access real-time information on FDA clearances, technology evaluations, and strategic collaborations. Our curated news ensures you stay informed about advancements in extracorporeal oxygenation and AI-driven blood analytics without speculative commentary.
Discover updates across key categories including regulatory submissions, clinical trial results, product launches, and global distribution agreements. All content is verified for accuracy and relevance to support informed decision-making.
Bookmark this page for streamlined access to Inspira Technologies' progress in redefining respiratory support systems. Check back regularly for authoritative reporting on innovations addressing acute respiratory failure and ICU resource challenges.
Inspira Technologies OXY B.H.N. Ltd. (Nasdaq: IINN) has announced the appointment of Dr. Stephane Ledot to its Scientific Advisory Board. Dr. Ledot, an expert in critical care and anesthesia, brings extensive experience to the role, having previously served as director of the ECMO service at Royal Brompton Hospital. His expertise is expected to enhance the company’s efforts in developing the ART device, an innovative extracorporeal respiratory support system. The device aims to support patients with acute respiratory failure without the need for mechanical ventilation.
Inspira Technologies OXY B.H.N. Ltd. (NASDAQ: IINN) announced that Co-Founder and CFO Joe Hayon will present at the H.C. Wainwright 7th Annual Israel Virtual Conference on November 15 at 2:30 PM EST. One-on-one meetings are available for attendees. A replay of the presentation will be accessible on Inspira's investor relations page post-event. Inspira Technologies is developing the ART device, an innovative respiratory support system designed to act as an 'Artificial Lung' for patients, though it has yet to be tested in humans and is not FDA-approved.
Inspira Technologies OXY B.H.N. Ltd. (Nasdaq: IINN) has filed a Patent Cooperation Treaty application for its innovative dual lumen cannula designed to enhance respiratory care. This novel device aims to improve patient outcomes by preventing complications like air embolisms, bleeding, and infection. The dual lumen cannula allows for bedside insertion into large blood vessels, quickly rebalance oxygen saturation while reducing human error. CEO Dagi Ben-Noon highlighted the goal to offer cost-effective support for patients with acute respiratory failure, though the product is still in development and not FDA approved.
Inspira Technologies (Nasdaq: IINN) has signed an exclusive distribution agreement with Anita Técnica S.L. (WAAS Group) to deploy ART devices in Spain and Portugal over a period of seven years. The agreement entails WAAS Group purchasing a minimum of 1,040 ART devices and 35,360 disposable units, pending regulatory approval. The ART device aims to support patients with respiratory failure while awake, potentially reducing mechanical ventilation reliance. This collaboration leverages WAAS Group's market penetration capabilities in the region, positioning Inspira for rapid adoption.
Inspira Technologies OXY B.H.N. Ltd. (Nasdaq: IINN) will present its ART device at the HLTH conference in Boston from October 17-20, 2021. Co-Founder and CFO Joe Hayon will discuss the company's innovative respiratory support technology that aims to function as an 'Artificial Lung' for patients. This system is designed to enhance patient care while minimizing the need for mechanical ventilation. Inspira Technologies is part of the Israeli Medical Device & Digital Health sector and will showcase its technology at Booth 1147-15.
Inspira Technologies OXY B.H.N. Ltd. (Nasdaq: IINN) announced it will host a TechTalk event titled "Has COVID-19 changed the game?" on October 6, 2021, at 1:00 PM EDT. This online conference will focus on the impacts of COVID-19 on medical practices, technology innovations, and capital markets. Key speakers include Dr. Yigal Kassif discussing new COVID-19 treatment paradigms, Tal Dolev on medical startup technologies, and Miri Segal-Scharia covering capital market effects. The event aims to engage healthcare professionals and investors. For registration, visit: registration link.
Inspira Technologies OXY B.H.N. Ltd (Nasdaq: IINN) has contracted GlobalLogic, a Hitachi Group Company, to enhance the digital platform of its ART device, which functions as an artificial lung. This advanced algorithm-based control platform aims to optimize patient oxygen saturation and features advanced sensor data collection. CEO Dagi Ben-Noon highlighted the significance of this project amidst the COVID-19 pandemic, aiming to improve patient care. GlobalLogic's expertise in medical technology is expected to accelerate product development and enhance healthcare experiences.
Inspira Technologies has submitted a patent application for a new supportive device aimed at improving treatment and mobility for cannulated patients, enhancing procedures for medical staff. This device is designed to assist patients requiring Extracorporeal Membrane Oxygenation (ECMO) and other treatments such as COVID-19, COPD, and ARDS. CEO Dagi Ben-Noon emphasized its potential impact on patient outcomes and rapid patent acquisition through the Israeli Patent Office, recognized for its efficiency. The ART device, functioning as an 'artificial lung,' remains untested in humans and lacks FDA approval.
Inspira Technologies OXY B.H.N. Ltd. (Nasdaq: IINN) has announced participation in two upcoming virtual conferences. Joe Hayon, Co-Founder and CFO, will be featured at the H.C. Wainwright 23rd Annual Global Investment Conference with an on-demand presentation available from September 13, 2021. He will also present at the Benzinga Small/Mid Cap Healthcare Conference on September 29, 2021, at 10:50 am ET. The company specializes in proprietary respiratory support technologies designed to stabilize patient oxygen levels without invasive mechanical ventilation.
Inspira Technologies OXY B.H.N. Ltd (Nasdaq: IINN) announced the successful completion of a pump bench study for its ART device, aimed at providing extracorporeal respiratory support. This milestone allows the company to advance towards the manufacturing phase of the ART device, designed to function as an "external lung" and enable patients to remain awake during treatment. The study compared Inspira's pump with leading centrifugal pumps, emphasizing its potential to minimize blood damage. However, the ART device has not yet undergone human testing or received FDA approval.
